{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"A TESAE was any untoward medical occurrence that at any dose: resulted in death; life threatening condition; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect or was medically important due to other reasons than the above mentioned criteria. An adverse event was defined as any untoward medical occurrence in a participant administered an investigational product.","groups":[{"description":"Participants with recurrent or refractory ewing sarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG000","title":"Phase 2: Cohort 1, Ewing Sarcoma"},{"description":"Participants with recurrent or refractory rhabdomyosarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG001","title":"Phase 2: Cohort 2, Rhabdomyosarcoma"},{"description":"Participants with recurrent or refractory HGG received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG002","title":"Phase 2: Cohort 3, HGG"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SAS included all participants who received at least one dose of study drug (Lenvatinib or Everolimus).","reportingStatus":"POSTED","timeFrame":"From date of first dose up to 28 days after the last dose of study treatment (up to 7.5 months)","title":"Phase 2: Number of Participants With Any Treatment-emergent Serious Adverse Event (TESAE)","type":"SECONDARY","unitOfMeasure":"Participants"}